# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹320.5 Cr** Q3 FY26 (+46% YoY, +15% QoQ) * EBITDA: ₹742 Mn (+35% YoY), adjusted margin at 29.2% * Net Profit: **₹431 Mn** (+41% YoY), adjusted PAT +80% YoY ## B. Revenue Growth * **Record Top-Line Performance:** Highest-ever quarterly revenue driven by strong double-digit growth in both new and existing hospitals. * **New Facility Contribution:** Newly operational hospitals delivered meaningful revenue in first full quarter, supporting scalable expansion model. * **Sustained Core Momentum:** Existing hospitals maintained robust growth, reflecting resilient demand and effective service delivery. ## C. EBITDA & Margins * **Margin Resilience:** Adjusted EBITDA margin reached **27%**, with strong operating leverage and service mix improvements offsetting ramp-up losses. * **Core Profitability Strength:** Older hospitals generated significantly higher margins, effectively neutralizing drag from new facilities. * **Oncology & ARPOB Growth:** Service line expansion in high-margin areas like oncology and rising **ARPOB (+15% YoY in Noida Extension)** contributed to margin uplift. ## D. Net Profit & Tax * **Accelerating Bottom Line:** Net profit growth outpaced revenue, while adjusted PAT surged, indicating improving earnings quality post-ramp-up. * **Acquisition Readiness:** Recently acquired hospital is EBITDA and P&L positive, with **₹45–50 Cr annualized revenue**, enabling immediate contribution from Feb-26. ## E. Cash Flow & Receivables * **Receivables Discipline:** Trade receivables reduced by **₹15 Cr** from FY24 levels through enhanced collections and billing systems. * **Cash Flow Conversion:** OCF to EBITDA improved to **60%–70%**, reflecting stronger working capital management. * **Forward Guidance on DSO:** Management confident in reducing consolidated receivable days to **105–110 by Mar-27**, from current ~115 days. --- # 2. Occupancy & Bed Utilization ## A. Key Figures * **Blended Occupancy:** **67%** network-wide (Q3) · **91%** Noida · **74%** Greater Noida · **72%** Jhansi-Orchha · **61%** Noida Extension * **ARPOB:** **~₹33K** blended · **~₹39K** Greater Noida · **~₹32K** Noida · **~₹44K** Noida Extension · **~₹14K** Jhansi-Orchha · **~₹35K** Greater Faridabad · **~₹40K** Model Town * ALOS: around 4 to 4.5 days currently, potentially declining over next two years * **New Facility Occupancy:** **43%** Faridabad Sector-20 · **38%** Model Town (Delhi) ## B. Market Position & Utilization Trends * **Regional Leadership:** Emerged as the most preferred healthcare chain in Faridabad, capturing strong patient volumes despite new competition and early-stage ramp-up. * **Resilient Growth:** Reported over 30% patient volume growth amid regional supply increase, signaling market expansion rather than share loss. * **High-Value Mix:** Noida Extension achieves highest ARPOB despite mid-tier occupancy, reflecting premium service mix and pricing power. ## C. Margin Drivers & Strategic Shifts * **Core Margins Stable:** Mature hospitals drive consolidated group margins to 29%, with limited near-term upside expected despite rising occupancy. * **Payer Mix Strategy:** Deliberate reduction in government pay across new and existing hospitals supports quality growth and ARPOB improvement, offsetting margin expansion. ## D. New Facility Ramp-up * **Early-Stage Momentum:** Newer facilities in Greater Faridabad, Faridabad Sector-20, and Model Town show solid initial adoption, operating below full capacity and without full insurance tie-ups. * **Scalable Model:** Breakeven expected at 30–35% of full operational bed capacity, indicating low-risk expansion trajectory. --- # 3. Revenue & Payer Mix ## A. Key Figures * **ARPOB:** ₹33,744 group-wide (+10% YoY) · ₹44,000 Noida Extension (+16% YoY) · ₹40,000 New Delhi/Faridabad * **Payer Mix:** **35%** government · **65%** cash/TPA combined * **Receivable Days:** **~200 days** government · **110 days** overall average ## B. Government vs Private * **Strategic De-risking:** Management is actively reducing exposure to government payers, targeting **25%–28%** of revenue group-wide and **15%–20%** in new facilities. * **Payment Cycle Drag:** ESI and CGHS contribute to extended receivable days, with government collections averaging **~200 days**, significantly above the group average. ## C. Cash & Insurance Split * **Margin Optimization:** Payer mix in new hospitals prioritizes **cash and TPA insurance**, supported by a shift away from low-margin group policies toward more profitable **retail insurance** (60% of mix). * **Collections Outlook:** Receivable days expected to improve to **80–82 days** in 2–3 years, driven by reduced government dependence and tighter revenue cycle management. * **Declining Deductions:** Group-level insurance deduction rates are on a sustained downward trend, enhancing net revenue realization despite variability in pace. ## D. ARPOB Trends * **Value-Based Growth:** Blended ARPOB expansion reflects successful shift toward **super-specialty services**, with Noida Extension and Model Town exceeding **₹40,000**, underpinned by **70% super-specialty revenue contribution**. * **Geographic Tiering:** ARPOB varies meaningfully by location, with Tier 1 and extension markets outperforming; Agra projected at **₹30,000–32,000**, reflecting strong Tier 2 potential. --- # 4. Expansion & Capacity Growth ## A. Key Figures * **Total Bed Capacity:** **2,550** current · **5,000–6,000** targeted in 3–4 years * **Planned Bed Additions:** **~3,000** new beds over 3–5 years * **Capex:** **₹1,500 Cr** planned over 5 years (~**₹60 L per bed** average) * **Capex per Bed:** **₹60 L** historical average · **₹80–90 L** for new Delhi/Faridabad facilities ## B. Bed Capacity Plan * **Aggressive Network Buildout:** Expansion focused on NCR first, then broader North India, leveraging greenfield, brownfield, and asset-light models to scale to **5,000+ beds** within 5 years. * **Near-Term Operationalization:** New Delhi and Faridabad Sector-20 hospitals already contributing strongly; full ramp-up expected over 4–5 years. * **Financial Impact:** Recent CGHS price revision providing **positive top- and bottom-line momentum**, partially offsetting expected EBITDA pressure from upcoming facility ramp-ups. ## C. Greenfield/Brownfield Mix * **Agra Integration Complete:** Fully operational and contributing meaningfully to financials from current quarter, adding **250 beds** to network. * **Brownfield Progress:** Noida and Greater Noida expansions underway, with commissioning targeted within 5 years. * **Asset-Light Acceleration:** Strategic shift toward equipment-only partnerships reducing capital intensity and enabling faster deployment. ## D. Capex per Bed * **Cost Escalation in Core Markets:** New facilities in Delhi and Faridabad face **25–50% higher capex per bed** due to elevated land and construction costs. * **Efficiency Through Model Innovation:** Despite higher unit costs in key locations, overall average capex per bed maintained at **₹60 L** through asset-light structuring and mix optimization. --- # 5. Service Line & Clinical Focus ## A. Key Figures * **Oncology Revenue Contribution:** **~10%** of specialty revenue (+ from <4% in 2–3 years) · **Target: ~15%** in 2–5 years * **Medical Tourism Revenue Share:** **Single-digit percentage** of total revenue * **MVT Cost Benefit:** **5%–6%** estimated increase in the cost that we would be benefiting from ## B. Super Specialty Shift * **Clinical Leadership Reinforced:** Strategic focus on super specialties bolstered by appointments of **star clinicians**, national accolades, and **robotics-enabled quaternary care** from inception. * **Infrastructure & Integration:** Agra Hospital recognized as a regional leader with **NABH certification**, advanced diagnostics, and expansion capacity; integration with NCR facilities underway via top doctor hires. * **Case Mix Transformation:** Yatharth is actively shifting toward high-acuity services—**cardiology, neurosurgery, gastroenterology**—now outpacing general specialties **quarter-on-quarter**, reflecting a deliberate clinical and revenue repositioning. ## C. Oncology Growth * **Rising Strategic Priority:** Oncology shows **strong double-digit growth** in volume and revenue, now a top-tier specialty with **full-scale services including bone marrow transplants** set to launch in Faridabad and New Delhi within 5–6 months. * **Clinical Differentiation:** Demonstrated leadership in complex, minimally invasive procedures such as **POEM and rare endourological surgeries**, reinforcing regional reputation and attracting high-acuity cases. ## D. Medical Tourism * **Preemptive Global Expansion:** Ahead of the **Jewar Airport launch in two months**, the company accelerated outreach via **OPDs in Mauritius, Nigeria, Turkmenistan**, and partnerships across Africa and Central Asia. * **Growing International Footprint:** Medical value travel shows **rising patient volumes** and geographic diversification, supported by policy tailwinds yielding an estimated **5%–6% cost advantage**, with revenue contribution expected to scale post-airport activation. --- # 6. Risks & Healthcare Factors ## A. Key Figures * **EBITDA Margin Impact:** New hospitals cause initial drag; margins would be **3%–5% higher** excluding them * **Loss Reduction:** Model Town Hospital saw **50% reduction in losses** QoQ post-launch * Receivables Benchmark: Peer best practice at sub-130–140 days for government receivable collection ## B. New Hospital Drag * **Favorable Acquisition Economics:** Agra Hospital bypasses typical **15-month, high-cash loss phase**, contributing positively to margins from inception. * **Normalized Margin Strength:** Underlying EBITDA margins significantly stronger—would exceed consolidated average by **300–500 bps** if new unit drag excluded. * **Stabilizing New Units:** Sector-20 and Model Town hospitals past peak investment phase; future losses tied directly to volume growth, not structural costs. * **Maturation Trajectory:** Established units (2–5 years) approaching **mature-margin profile (~20%+)**, validating long-term unit economics. ## C. Doctor Poaching * **Competitive Physician Mobility:** Doctor poaching acknowledged as industry norm; Yatharth both faces and employs similar talent acquisition strategies in expansion markets. * **Strategic Differentiation:** Management views new entrants as expanding regional healthcare demand, not zero-sum threats, emphasizing quality care as key to retention. ## D. Government Receivables * **Process-Led Delays:** Receivables backlog stemmed from rapid government business onboarding outpacing legacy collection systems. * **Active Remediation:** Recovery operations enhanced via **outsourced, proven third-party teams** benchmarked to listed peers with sub-140-day collection cycles. * **Conservative Accounting:** No significant write-offs; **provisions for doubtful debts** prudently managed and reversed upon collection. * **Deductions vs. Defaults:** Revenue adjustments mainly from **payer disputes (e.g., insurers)**, not uncollectible debt, supporting underlying collectability. --- # 7. Guidance & Outlook ## A. Key Figures * **ARPOB Growth:** **10% YoY** projected for FY27 and FY28 * **EBITDA Margin Target:** **24%–25%** consolidated blended margin expected by FY27 * **Occupancy Outlook:** **>50%** expected in coming quarters; full empanelment by end of Q4 or early Q4 FY26 ## B. Revenue & ARPOB Forecast * **Sustained ARPOB Expansion:** Double-digit annual ARPOB growth anticipated, driven by strong performance at Noida Extension and Greater Noida facilities and favorable payer mix from rising oncology services. * **Q4 Momentum:** Performance expected to improve sequentially in Q4, supported by hospital additions and ramp-up of recent facilities. ## C. Margin Stabilization * **Margin Trajectory Improving:** Consolidated EBITDA margins on path to stabilize at 24%–25% despite expansion, with upside from revised CGHS rates effective January 1. * **Near-Term Margin Upside:** EBITDA margins expected to improve in Q4 and Q1 next fiscal, reflecting operational leverage and pricing tailwinds. ## D. Breakeven Timeline * **Faridabad Success Story:** Greater Faridabad facility achieved breakeven in Q1 FY26 and now contributes meaningfully to profitability, with EBITDA margin nearing group average. * **Pipeline Breakevens:** Newer hospitals on track, with Faridabad expected at breakeven within 12 months and Model Town within 15 months, supported by positive recent trends.